Jonathan Glen

Jonathan Glen has extensive experience in the technology and biotechnology industries. In 2014, they founded PiBond, a company that specializes in producing high purity siloxane and metal organic polymer materials for the semiconductor industry. Jonathan served as the Executive Chairman and played a crucial role in supplying advanced materials for the latest technology nodes in the industry.

In the same year, Jonathan also founded ReBio Technologies Limited, a biotechnology company focused on developing a proprietary formulation technology called SiSu®, which addresses safety and efficacy challenges in sustained release approaches. This technology has the potential to improve the standard of care for vision-threatening chronic eye diseases.

Prior to their entrepreneurial ventures, Jonathan served as a Founding Partner at Diverso Management from 2003 to 2013. Jonathan was responsible for establishing the company and contributed to its success during their tenure.

Additionally, Jonathan acted as a Founding Investor in ReneSola Ltd. from 2005 to 2011.

Currently, Jonathan is the Chairman of the Board at Aleva Neurotherapeutics SA, a position they have held since February 2021.

Overall, Jonathan Glen has a diverse background in founding and leading companies in the technology and biotechnology sectors, demonstrating their expertise in business development, innovation, and strategic leadership.

Jonathan Glen obtained a Bachelor of Science (BSc) degree from Queen Mary University of London from 1995 to 1997. No specific field of study is provided.